LivingGLP1
Study S000739

Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World

ClinicalTrials.gov record

Registration

Registration
NCT06874751
Acronym
SCORE
Study type
OBSERVATIONAL
Status
COMPLETED
Enrollment
45456
Start
2024-12-06
Primary completion
2025-03-28
Lead sponsor
Novo Nordisk A/S
Conditions
Overweight; Obesity; Atherosclerotic Cardiovascular Disease (ASCVD)
Interventions
OTHER:No treatment given
Results posted
FALSE
Individual participant data sharing
YES
Secondary identifiers
OTHER:U1111-1318-9978

Registered primary outcomes

  • Revised 5-Point Major Adverse Cardiovascular Events (MACE-5) (time-to-event) [Index date, earliest of revised MACE-5 and end of follow-up, up to 30 months]
  • Revised 3-Point Major Adverse Cardiovascular Events (MACE-3) (time-to-event) [Index date, earliest of revised MACE-3 and end of follow-up, up to 30 months]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0015878Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real-world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World).
Smolderen KG, Diabetes, obesity & metabolism
2025Nonrandomized studyPMID 40926360DOIcites ClinicalTrials.gov:NCT06874751; registry reference DERIVED:40926360